Peter J. van den Elsen

12.0k citations

193 papers · 9.8k indexed · 1 hit paper · h-index 57

Immunology top 0.2%
Molecular Biology top 2%
Oncology top 1%
Genetics top 1%
Radiology, Nuclear Medicine and Imaging top 2%

Co-authors: Sam J. P. Gobin Ada Houweling Koichi S. Kobayashi Tjadine M. Holling Cox Terhorst Alex J. van der Eb Ad Peijnenburg Nienke van der Stoep
Topics: T-cell and B-cell Immunology (103 papers)Immune Cell Function and Interaction (98 papers)Immunotherapy and Immune Responses (64 papers)
Cited by: Immunology Oncology Genetics
Journals: Nature New England Journal of Medicine Cell
Partner nations: Netherlands United States United Kingdom

In The Last Decade

Peter J. van den Elsen

192 papers receiving 9.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Partial transformation of primary rat cells by the leftmost 4.5% fragment of adenovirus 5 DNA

1980 415 citations Peter J. van den Elsen et al. profile →

Peers

Countries citing papers authored by Peter J. van den Elsen

Since Specialization

Citations

This map shows the geographic impact of Peter J. van den Elsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter J. van den Elsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter J. van den Elsen more than expected).

Fields of papers citing papers by Peter J. van den Elsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter J. van den Elsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter J. van den Elsen. The network helps show where Peter J. van den Elsen may publish in the future.

Co-authorship network of co-authors of Peter J. van den Elsen

This figure shows the co-authorship network connecting the top 25 collaborators of Peter J. van den Elsen. A scholar is included among the top collaborators of Peter J. van den Elsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter J. van den Elsen. Peter J. van den Elsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Chemical and genetic control of IFN γ‐induced MHCII expression 2018 ·EMBO Reports ·Ruud H. Wijdeven,Marvin M. van Luijn,Annet F. Wierenga‐Wolf,Jimmy J.L.L. Akkermans,Peter J. van den Elsen,Rogier Q. Hintzen,Jacques Neefjes	25
2	Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients (vol 110, pg 459, 2014) 2014 ·British Journal of Cancer ·Eliane C.M. Zeestraten,(unknown),(unknown),Inès J. Goossens-Beumer,(unknown),Gerrit‐Jan Liefers,Peter J. van den Elsen,Cornelis J.�H. van de Velde,Peter J.K. Kuppen	4
3	Epigenetic control of CCR5 transcript levels in immune cells and modulation by small molecules inhibitors 2011 ·Journal of Cellular and Molecular Medicine ·Rutger J. Wierda,Hedwich F. Kuipers,Marja C.J.A. van Eggermond,Anne Benard,(unknown),(unknown),Sacha B. Geutskens,J. Wouter Jukema,Víctor E. Márquez,Paul H.A. Quax,Peter J. van den Elsen	22
4	Epigenetics in atherosclerosis and inflammation 2010 ·Journal of Cellular and Molecular Medicine ·Rutger J. Wierda,Sacha B. Geutskens,J. Wouter Jukema,Paul H.A. Quax,Peter J. van den Elsen	130
5	Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease 2008 ·European Heart Journal ·Douwe Pons,F. R. de Vries,Peter J. van den Elsen,Bastiaan T. Heijmans,Paul H.A. Quax,J. Wouter Jukema	138
6	A Role for EZH2 in Silencing of IFN-γ Inducible MHC2TA Transcription in Uveal Melanoma 2007 ·The Journal of Immunology ·Tjadine M. Holling,(unknown),Louis Wilson,Marja C.J.A. van Eggermond,Erik van Schooten,Renske D.M. Steenbergen,Peter J.F. Snijders,Martine J. Jager,Peter J. van den Elsen	52
7	Epigenetic silencing of MHC2TA transcription in cancer 2006 ·Biochemical Pharmacology ·Tjadine M. Holling,Marja C.J.A. van Eggermond,Martine J. Jager,Peter J. van den Elsen	24
8	Differential Expression Regulation of the α and β Subunits of the PA28 Proteasome Activator in Mature Dendritic Cells 2005 ·The Journal of Immunology ·Ferry Ossendorp,(unknown),Marcel Camps,Francesca Granucci,Sam J. P. Gobin,Peter J. van den Elsen,Danita H. Schuurhuis,Gosse J. Adema,Grayson B. Lipford,Tomoki Chiba,Alice J.A.M. Sijts,Peter-M. Kloetzel,Paola Ricciardi‐Castagnoli,Cornelis J.M. Melief	60
9	Activated Human T Cells Accomplish MHC Class II Expression Through T Cell-Specific Occupation of Class II Transactivator Promoter III 2002 ·The Journal of Immunology ·Tjadine M. Holling,Nienke van der Stoep,Edwin Quinten,Peter J. van den Elsen	124
10	Transcriptional Regulation of the MHC Class II Trans -Activator (CIITA) Promoter III: Identification of a Novel Regulatory Region in the 5′-Untranslated Region and an Important Role for cAMP-Responsive Element Binding Protein 1 and Activating Transcription Factor-1 in CIITA-Promoter III Transcriptional Activation in B Lymphocytes 2002 ·The Journal of Immunology ·Nienke van der Stoep,Edwin Quinten,Peter J. van den Elsen	45
11	A Novel Autocrine Pathway of Tumor Escape from Immune Recognition: Melanoma Cell Lines Produce a Soluble Protein That Diminishes Expression of the Gene Encoding the Melanocyte Lineage Melan-A/MART-1 Antigen Through Down-Modulation of Its Promoter 2001 ·The Journal of Immunology ·James T. Kurnick,Teresa Ramirez‐Montagut,Lenora A. Boyle,David Andrews,Franco Pandolfi,Paul J. Durda,David Butera,Ian S. Dunn,Elizabeth M. Benson,Sam J. P. Gobin,Peter J. van den Elsen	46
12	The MHC-Specific Enhanceosome and Its Role in MHC Class I and β2-Microglobulin Gene Transactivation 2001 ·The Journal of Immunology ·Sam J. P. Gobin,Marlijn van Zutphen,Sandy D. Westerheide,Jeremy M. Boss,Peter J. van den Elsen	74
13	Longitudinal analysis of T cells responding to tetanus toxoid in healthy subjects as well as in pediatric patients after bone marrow transplantation: the identification of identical TCR–CDR3 regions in time suggests long-term stability of at least part of the antigen-specific TCR repertoire 2001 ·International Immunology ·Barbara C. Godthelp,Maarten J. D. van Tol,Jaak M. Vossen,Peter J. van den Elsen	9
14	Transcriptional regulation of HLA-G 1999 ·Transplantation Proceedings ·Sam J. P. Gobin,V. Keijsers,Clara Yujing Cheong,Marlijn van Zutphen,Peter J. van den Elsen	15
15	The role of enhancer A in the locus-specific transactivation of classical and nonclassical HLA class I genes by nuclear factor kappa B. 1998 ·PubMed ·(unknown),V. Keijsers,Marlijn van Zutphen,Peter J. van den Elsen	103
16	Site α Is Crucial for Two Routes of IFNγ-Induced MHC Class I Transactivation: The ISRE-Mediated Route and a Novel Pathway Involving CIITA 1997 ·Immunity ·Sam J. P. Gobin,Ad Peijnenburg,V. Keijsers,Peter J. van den Elsen	189
17	Alterations in cord blood leukocyte subsets of patients with severe hemolytic disease after intrauterine transfusion therapy 1997 ·The Journal of Pediatrics ·Henk E. Viëtor,(unknown),Gienke R. Vreugdenhil,Humphrey H.H. Kanhai,Peter J. van den Elsen,Anneke Brand	6
18	Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance 1992 ·Immunogenetics ·Cécile A. C. M. van,J. D‘Amaro,J. Pool,Els Blokland,A Bakker,Peter J. van den Elsen,J. J. van Rood,Els Goulmy	100
19	Human suppressor T cell clones lack CD28 1990 ·European Journal of Immunology ·(unknown),Tom H. M. Ottenhoff,Peter J. van den Elsen,Frits Koning,Li Zhang,Tak W. Mak,René R. P. de Vries	26
20	Assignment of the gene coding for the T3-delta subunit of the T3-T-cell receptor complex to the long arm of human chromosome 11 and to mouse chromosome 9. 1985 ·Proceedings of the National Academy of Sciences ·Peter J. van den Elsen,G.A.P. Bruns,Daniela S. Gerhard,Dimitrina D. Pravtcheva,C. Jones,David E. Housman,(unknown),Stuart H. Orkin,Cox Terhorst	56

About Peter J. van den Elsen

Peter J. van den Elsen is a scholar working on Immunology, Transplantation and Oncology, having authored 193 papers that have together received 9.8k indexed citations. Recurring topics across this work include T-cell and B-cell Immunology (103 papers), Immune Cell Function and Interaction (98 papers) and Immunotherapy and Immune Responses (64 papers). The work is most often cited by research in Immunology (6.3k citations), Oncology (2.0k citations) and Genetics (1.3k citations). Peter J. van den Elsen has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Sam J. P. Gobin, Ada Houweling, Koichi S. Kobayashi, Tjadine M. Holling, Cox Terhorst, Alex J. van der Eb, Ad Peijnenburg, Nienke van der Stoep, Marlijn van Zutphen and Marja C.J.A. van Eggermond. Their work appears in journals such as Nature, New England Journal of Medicine and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact